SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

ZLD Zelira Therapeutics Limited

Healthcare · Biotechnology · website
$0.50
52wk 0.31 – 1.15
Overall
24.9
Value
81.2
Growth
0.0
Health
0.0
Quality
0.0
Momentum
41.4
Dividend
—
Price
About Zelira Therapeutics Limited

Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, including SprinJeneCBD, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is based in Perth, Australia.

Price analytics

Returns

1 day 0.0%
1 week 0.0%
1 month 0.0%
3 months 0.0%
6 months 0.0%
1 year 31.6%
3 years -49.0%

Risk

Volatility (1y ann.) 144.3%
Beta vs ASX 200 0.16
Sharpe (1y) 0.59
VaR 95% (1-day) -6.6%
Max drawdown (1y) -44.8%
Off 1-year high -44.8%

Technicals

RSI(14) 100 OB
vs 50DMA 0.0%
vs 200DMA -1.8%
Trend Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 81.2
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
100
Price / Sales
0
Growth 0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
0
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health 0.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
0
Debt / Equity
—
Quality (Profitability & Cash Flow) 0.0
Return on equity
—
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 41.4
6-month return vs ASX 200
46
Price vs 200-day average
44
Price vs 50-day average
50
Position in 52-week range
23

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$6.57M
P/E (trailing)
—
P/E (forward)
-10.00
EPS (trailing)
-0.32
Dividend yield
—
Payout ratio
0.0%
Beta
0.59
EV / EBITDA
-1.98
Price / Book
-1.33
ROE
—
Operating margin
-658,713.1%
Net margin
0.0%
Total cash
$5,663
Total debt
$2.14M
Current ratio
0.11
Debt / Equity
—
Free cash flow
$-764,668
Avg volume
—
Latest annual results (FY ending 30 Jun 2025)
  • Revenue$656.00
  • Gross profit-$8.17K
  • Operating income-$3.81M
  • Net income-$3.63M
  • Diluted EPS-0.32
  • Free cash flow-$4.91M
  • Net debt$2.14M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4